80. Alliance Pharma
Just six months ago, Alliance Pharma (APH) looked like a company in crisis. Its chief executive, Peter Butterfield, stepped down amid multiple delays to the publication of its annual results.
The Competition and Markets Authority had previously sought to disqualify Butterfield as a director following an investigation into alleged anti-competitive behaviour. Although he was subsequently cleared of any wrongdoing, the negative publicity didn’t do wonders for Alliance’s share price. With a new chief executive installed in May, the worst now appears to be over and the business has started its recovery.